Review: Castration-resistant prostate cancer: New science and therapeutic prospects

Therapeutic Advances in Medical Oncology

Volumn 2, Issue 3, 2010, Pages 189-207

  Bellmunt, Joaquim ^a   Oh, William K ^b  

^a HOSPITAL DEL MAR   (Spain)

^b Division of Hematology and Oncology   (United States)

Author keywords

castration resistant prostate cancer; chemotherapy; new agents; targeted therapies

Indexed keywords

ABIRATERONE; ANDROGEN; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CALCITRIOL; CHAPERONE; EPOTHILONE DERIVATIVE; GONADORELIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; GROWTH FACTOR; LENOLIDAMIDE; MDV 3100; OBLIMERSEN; PROSTATE SPECIFIC ANTIGEN; PROSTVAC; SATRAPLATIN; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CASTRATION; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

EID: 77955602629     PISSN: 17588340     EISSN: None     Source Type: Journal    
DOI: 10.1177/1758834009359769     Document Type: Review

References (150)

1. Armstrong, A.J. and George, D.J. ( 2007) Satraplatin in the treatment of hormone-refractory metastatic prostate cancer. Ther Clin Risk Manag 3: 877-883.
2. Armstrong, A.J. and George, D.J. ( 2008) New drug development in metastatic prostate cancer. Urol Oncol 26: 430-437.
3. Attar, R.M., Jure-Kunkel, M., Balog, A., Cvijic, M.E., Dell-John, J., Rizzo, C.A. et al. (2009) Discovery of BMS-641988, a novel and potent inhibitor of androgen receptor signaling for the treatment of prostate cancer. Cancer Res 69: 6522-6530.
4. Attard, G., Sarker, D., Reid, A., Molife, R., Parker, C. and de Bono, J.S. ( 2006) Improving the outcome of patients with castration-resistant prostate cancer through rational drug development. Br J Cancer 95: 767-774.
5. Attard, G., Reid, A.H., Olmos, D. and de Bono, J.S. (2009 a) Antitumor activity with CYP 17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res 69: 4937-4940.
6. Attard, G., Reid, A.H., A'Hern, R., Parker, C., Oommen, N.B., Folkerd, E. et al. (2009 b) Selective inhibition of CYP 17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 27: 3742-3748.
7. Bartlett, J.B., Dredge, K. and Dalgleish, A.G. ( 2004) The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 4: 314-322.
8. Beardsley, E.K. and Chi, K.N. ( 2008) Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer. Curr Opin Support Palliat Care 2: 161-166.
9. Beer, T.M. ( 2005) ASCENT: the androgen-independent prostate cancer study of calcitriol enhancing taxotere. BJU Int 96: 508-513.
10. Beer, T.M., Ryan, C.W., Venner, P.M., Petrylak, D.P., Chatta, G.S., Ruether, J.D. et al. (2007) Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol 25: 669-674.
11. Beer, T.M., Slovin, S.F., Higano, C.S., Tejwani, S., Dorff, T.B., Stankevich, E. et al. (2008) Phase I trial of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol 26(Suppl May 20): abstr 5004.
12. Bellmunt, J., Carles, J. and Albanell, J. (2009 a) Predictive modelling in hormone-refractory prostate cancer (HRPC). Clin Transl Oncol 11: 82-85.
13. Bellmunt, J., Flodgren, P., Roigas, J. and Oudard, S. (2009 b) Optimal management of metastatic renal cell carcinoma: an algorithm for treatment. BJU Int 104: 10-18.
14. Bellmunt, J., Rosenberg, J.E. and Choueiri, T.K. (2009 c) Recent progress and pitfalls in testing novel agents in castration-resistant prostate cancer. Eur Urol 56: 606-608.
15. Bhandari, M.S. and Hussain, M. ( 2005) Epothilones and the next generation of phase III trials for prostate cancer. BJU Int 96: 296-302.
16. Bone, H.G., Bolognese, M.A., Yuen, C.K., Kendler, D.L., Wang, H., Liu, Y. et al. (2008) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 93: 2149-2157.
17. Bradley, D.A., Hussain, M., Dipaola, R.S. and Kantoff, P. ( 2007) Bone directed therapies for prostate cancer. J Urol 178: S42-S48.
18. Bradley, D.A., Dunn, R., Rathkopf, D., Stadler, W.M., Wilding, G., Smith, D.C. et al. (2008) Vorinostat in hormone refractory prostate cancer (HRPC): trial results and IL-6 analysis. Proceedings of the Genitourinary Cancers Symposium, Abstract 211.
19. Brown, J.M., Corey, E., Lee, Z.D., True, L.D., Yun, T.J., Tondravi, M. et al. (2001) Osteoprotegerin and rank ligand expression in prostate cancer. Urology 57: 611-616.
20. Canil, C.M., Moore, M.J., Winquist, E., Baetz, T., Pollak, M., Chi, K.N. et al. (2005) Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 23: 455-460.
21. Carducci, M.A., Nelson, J.B., Bowling, M.K., Rogers, T., Eisenberger, M.A., Sinibaldi, V. et al. (2002) Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. J Clin Oncol 20: 2171-2180.
22. Carducci, M.A., Padley, R.J., Breul, J., Vogelzang, N.J., Zonnenberg, B.A., Daliani, D.D. et al. (2003) Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 21: 679-689.
23. Carducci, M.A., Saad, F., Abrahamsson, P.A., Dearnaley, D.P., Schulman, C.C., North, S.A. et al. (2007) A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 110: 1959-1966.
24. Chang, S.S. and Kibel, A.S. (2009) The role of systemic cytotoxic therapy for prostate cancer. BJU Int 103: 8-17.
25. Chee, K.G., Longmate, J., Quinn, D.I., Chatta, G., Pinski, J., Twardowski, P. et al. (2007) The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California / Pittsburgh cancer consortium trial. Clin Genitourin Cancer 5: 433-437.
26. Chen, C.D., Welsbie, D.S., Tran, C., Baek, S.H., Chen, R., Vessella, R. et al. (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10: 33-39.
27. Chen, G., Sircar, K., Aprikian, A., Potti, A., Goltzman, D. and Rabbani, S.A. ( 2006) Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 107: 289-298.
28. Chen, Y., Wilding, G., Gee, J., DiPaola, R.P., Pins, M., Carducci, M.A. et al. (2008) A phase II trial of lapatinib (GW572016) in patients with recurrent prostate cancer as evident by a rising PSA. J Clin Oncol 26(Suppl May 20): abstr 5170.
29. Chen, Y., Clegg, N.J. and Scher, H.I. (2009) Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol 10: 981-991.
30. Chi, K.N., Eisenhauer, E., Fazli, L., Jones, E.C., Goldenberg, S.L., Powers, J. et al. (2005) A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 97: 1287-1296.
31. Chi, K.N., Ellard, S.L., Hotte, S.J., Czaykowski, P., Moore, M., Ruether, J.D. et al. (2008 a) A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann Oncol 19: 746-751.
32. Chi, K.N., Siu, L.L., Hirte, H., Hotte, S.J., Knox, J., Kollmansberger, C. et al. (2008 b) A phase I study of OGX-011, a 2′-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res 14: 833-839.
33. Chi, K.N., Bjartell, A., Dearnaley, D., Saad, F., Schroder, F.H., Sternberg, C. et al. (2009 a) Castration resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol 56: 594-605.
34. Chi, K.N., Hotte, S.J., Yu, E., Tu, D., Eigl, B., Tannock, I. et al. (2009 b) Mature results of a randomized phase II study of OGX-011 in combination with docetaxel / prednisone versus docetaxel / prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 27(15s): abstr 5012.
35. Dahut, W.L., Scripture, C., Posadas, E., Jain, L., Gulley, J.L., Arlen, P.M. et al. (2008) A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 14: 209-214.
36. de Bono, J.S., Bellmunt, J., Attard, G., Droz, J.P., Miller, K., Flechon, A. et al. (2007) Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J Clin Oncol 25: 257-262.
37. Dunlop, E.A. and Tee, A.R. (2009) Mammalian target of rapamycin complex 1: signalling inputs, substrates and feedback mechanisms. Cell Signal 21: 827-835.
38. Dunlop, E.A., Dodd, K.M., Seymour, L.A. and Tee, A.R. (2009) Mammalian target of rapamycin complex 1-mediated phosphorylation of eukaryotic initiation factor 4E-binding protein 1 requires multiple protein-protein interactions for substrate recognition. Cell Signal 21: 1073-1084.
39. Edwards, A., Li, J., Atadja, P., Bhalla, K. and Haura, E.B. ( 2007) Effect of the histone deacetylase inhibitor LBH 589 against epidermal growth factor receptor-dependent human lung cancer cells. Mol Cancer Ther 6: 2515-2524.
40. Efstathiou, E., Tsavachidou, D., Wen, S., Troncoso, P., Mills, G.B. and Logothetis, C.J. ( 2008) Integrated quantative and spatial proteomic analysis of PI3kinase signaling in high grade prostate cancer (PCa) treated with temsirolimus with or without androgen ablation. J Clin Oncol (Meeting Abstracts) 26: 5071.
41. Ellis, G.K., Bone, H.G., Chlebowski, R., Paul, D., Spadafora, S., Smith, J. et al. (2008) Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 26: 4875-4882.
42. Escudier, B., Eisen, T., Stadler, W.M., Szczylik, C., Oudard, S., Staehler, M. et al. (2009) Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27: 3312-3318.
43. Feldman, B.J. and Feldman, D. ( 2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1: 34-45.
44. Figg, W.D., Dahut, W., Duray, P., Hamilton, M., Tompkins, A., Steinberg, S.M. et al. (2001) A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 7: 1888-1893.
45. Figg, W.D., Kruger, E.A., Price, D.K., Kim, S. and Dahut, W.D. ( 2002) Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer. Invest New Drugs 20: 183-194.
46. Fizazi, K. ( 2007) The role of Src in prostate cancer. Ann Oncol 18: 1765-1773.
47. Fizazi, K., Beuzeboc, P., Lumbroso, J., Haddad, V., Massard, C., Gross-Goupil, M. et al. (2009) Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol 27: 2429-2435.
48. Fong, L. and Small, E.J. ( 2008) Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol 26: 5275-5283.
49. Garcia, J.A. and Danielpour, D. ( 2008) Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther 7: 1347-1354.
50. George, D.J., Halabi, S., Shepard, T.F., Vogelzang, N.J., Hayes, D.F., Small, E.J. et al. (2001) Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 7: 1932-1936.
51. George, D.A., Armstrong, A.J., Creel, P., Morris, K., Madden, J., Turnbull, J. et al. (2008) A phase II study of RAD 001 in men with hormone-refractory metastatic prostate cancer. Proceedings of the Genitourinary Cancers Symposium, Abstract 181.
52. Gleave, M.E., Miayake, H., Goldie, J., Nelson, C. and Tolcher, A. ( 1999) Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides. Urology 54: 36-46.
53. Goodin, S., Rao, K.V. and DiPaola, R.S. ( 2002) State-of-the-art treatment of metastatic hormone-refractory prostate cancer. Oncologist 7: 360-370.
54. Graff, J.R., Konicek, B.W., McNulty, A.M., Wang, Z., Houck, K., Allen, S. et al. (2000) Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem 275: 24500-24505.
55. Gregory, C.W., Whang, Y.E., McCall, W., Fei, X., Liu, Y., Ponguta, L.A. et al. (2005) Heregulin-induced activation of HER 2 and HER 3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. Clin Cancer Res 11: 1704-1712.
56. Grunwald, V., de Graffenried, L., Russel, D., Friedrichs, W.E., Ray, R.B. and Hidalgo, M. ( 2002) Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 62: 6141-6145.
57. Hadaschik, B.A. and Gleave, M.E. ( 2007) Therapeutic options for hormone-refractory prostate cancer in 2007. Urol Oncol 25: 413-419.
58. Hamada, A., Sissung, T., Price, D.K., Danesi, R., Chau, C.H., Sharifi, N. et al. (2008) Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res 14: 3312-3318.
59. Harzstark, A.L. and Small, E.J. (2009) Immunotherapeutics in development for prostate cancer. Oncologist 14: 391-398.
60. Heath, E.I., Hillman, D., Vaishampayan, U., Sheng, S., Sarkar, F.H., Gaskins, M. et al. (2007) A phase II trial of 17-allylamino-17-demethoxygeldanamycin (17-AAG) in patients with hormone-refractory metastatic prostate cancer. J Clin Oncol (Meeting Abstracts) 25: 15553.
61. Higano, C.S., Corman, J.M., Smith, D.C., Centeno, A.S., Steidle, C.P., Gittleman, M. et al. (2008) Phase 1 / 2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 113: 975-984.
62. Higano, C., Saad, F., Somer, B., Curti, B., Petrylak, D., Drake, C.G. et al. (2009) A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC). Genitourinary Cancers Symposium, Abstract LBA150.
63. Hofbauer, L.C. and Schoppet, M. ( 2004) Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292: 490-495.
64. Hsieh, A.C., Small, E.J. and Ryan, C.J. ( 2007) Androgen-response elements in hormone-refractory prostate cancer: implications for treatment development. Lancet Oncol 8: 933-939.
65. Humphreys, D.T., Carver, J.A., Easterbrook-Smith, S.B. and Wilson, M.R. ( 1999) Clusterin has chaperone-like activity similar to that of small heat shock proteins. J Biol Chem 274: 6875-6881.
66. Hussain, M., Tangen, C.M., Lara Jr, P.N., Vaishampayan, U.N., Petrylak, D.P., Colevas, A.D. et al. (2005) Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol 23: 8724-8729.
67. Jain, R.K., Tong, R.T. and Munn, L.L. ( 2007) Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res 67: 2729-2735.
68. James, N.D., Caty, A., Borre, M., Zonnenberg, B.A., Beuzeboc, P., Morris, T. et al. (2008) Safety and efficacy of the specific endothelin-A receptor antagonist ZD 4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. Eur Urol 55: 1112-1123.
69. Jiang, B.H. and Liu, L.Z. (2009) PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res 102: 19-65.
70. July, L.V., Akbari, M., Zellweger, T., Jones, E.C., Goldenberg, S.L. and Gleave, M.E. ( 2002) Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 50: 179-188.
71. Kalmadi, S. and Raghavan, D. ( 2008) Evolving perspectives of the role of novel agents in androgen-independent prostate cancer. Indian J Urol 24: 303-308.
72. Kantoff, P.W. ( 2009) Overall survival (OS) analysis of a phase II randomized controlled trial (RCT) of a poxviral-based PSA targeted immunotherapy in metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol 27(Suppl): abstract 5013.
73. Kiyama, S., Morrison, K., Zellweger, T., Akbari, M., Cox, M., Yu, D. et al. (2003) Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Res 63: 3575-3584.
74. Koutsilieris, M., Mitsiades, C.S., Bogdanos, J., Dimopoulos, T., Karamanolakis, D., Milathianakis, C. et al. (2004) Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D 3 prostate cancer patients with bone metastases. Clin Cancer Res 10: 4398-4405.
75. Kreisberg, J.I., Malik, S.N., Prihoda, T.J., Bedolla, R.G., Troyer, D.A., Kreisberg, S. et al. (2004) Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 64: 5232-5236.
76. Krueckl, S.L., Sikes, R.A., Edlund, N.M., Bell, R.H., Hurtado-Coll, A., Fazli, L. et al. (2004) Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res 64: 8620-8629.
77. Lassi, K. and Dawson, N.A. (2009) Emerging therapies in castrate-resistant prostate cancer. Curr Opin Oncol 21: 260-265.
78. Leibowitz, S.B. and Kantoff, P.W. ( 2003) Differentiating agents and the treatment of prostate cancer: Vitamin D 3 and peroxisome proliferator-activated receptor gamma ligands. Semin Oncol 30: 698-708.
79. Lerut, E., Roskams, T., Goossens, E., Bootle, D., Dimitrijevic, S., Stumm, M. et al. (2005) Molecular pharmacodynamic (MPD) evaluation of dose and schedule of RAD 001 (everolimus) in patients with operable prostate carcinoma (PC). J Clin Oncol (Meeting Abstracts) 23: 3071.
80. Lin, B., White, J.T., Lu, W., Xie, T., Utleg, A.G., Yan, X. et al. (2005) Evidence for the presence of disease-perturbed networks in prostate cancer cells by genomic and proteomic analyses: a systems approach to disease. Cancer Res 65: 3081-3091.
81. Majumder, P.K. and Sellers, W.R. ( 2005) Akt-regulated pathways in prostate cancer. Oncogene 24: 7465-7474.
82. Majumder, P.K., Febbo, P.G., Bikoff, R., Berger, R., Xue, Q., McMahon, L.M. et al. (2004) mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10: 594-601.
83. Malik, S.N., Brattain, M., Ghosh, P.M., Troyer, D.A., Prihoda, T., Bedolla, R. et al. (2002) Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 8: 1168-1171.
84. Marrocco, D.L., Tilley, W.D., Bianco-Miotto, T., Evdokiou, A., Scher, H.I., Rifkind, R.A. et al. (2007) Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Mol Cancer Ther 6: 51-60.
85. Maulard, C., Richaud, P., Droz, J.P., Jessueld, D., Dufour-Esquerre, F. and Housset, M. ( 1995) Phase I-II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer. Cancer Chemother Pharmacol 36: 259-262.
86. McMenamin, M.E., Soung, P., Perera, S., Kaplan, I., Loda, M. and Sellers, W.R. ( 1999) Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 59: 4291-4296.
87. Miyake, H., Chi, K.N. and Gleave, M.E. ( 2000a) Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin Cancer Res 6: 1655-1663.
88. Miyake, H., Nelson, C., Rennie, P.S. and Gleave, M.E. ( 2000b) Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res 60: 170-176.
89. Morris, M.J., Reuter, V.E., Kelly, W.K., Slovin, S.F., Kenneson, K., Verbel, D. et al. (2002) HER-2 profiling and targeting in prostate carcinoma. Cancer 94: 980-986.
90. Morris, M.J., Pandit-Taskar, N., Carrasquillo, J., Divgi, C.R., Slovin, S., Kelly, W.K. et al. (2009) Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol 27: 2436-2442.
91. Murillo, H., Huang, H., Schmidt, L.J., Smith, D.I. and Tindall, D.J. ( 2001) Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 142: 4795-4805.
92. Nam, S., Kim, D., Cheng, J.Q., Zhang, S., Lee, J.H., Buettner, R. et al. (2005) Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 65: 9185-9189.
93. Nelson, J.B., Hedican, S.P., George, D.J., Reddi, A.H., Piantadosi, S., Eisenberger, M.A. et al. (1995) Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1: 944-949.
94. Nelson, J.B., Chan-Tack, K., Hedican, S.P., Magnuson, S.R., Opgenorth, T.J., Bova, G.S. et al. (1996) Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 56: 663-668.
95. Nelson, J.B., Love, W., Chin, J.L., Saad, F., Schulman, C.C., Sleep, D.J. et al. (2008) Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 113: 2478-2487.
96. Ning, Y.M., Arlen, P.M. and Gulley, J. ( 2006) A phase II trial of docetaxel thalidomide bevacizumab and prednisone in patients with metastatic androgen independent prostate cancer. Proc Am Soc Clin Oncol 24: abstract 13037.
97. No authors listed. (2005) Early clinical data and potential clinical utility of novel histone deacetylase inhibitors in prostate cancer. Clin Prostate Cancer 4: 83-85.
98. O'Reilly, K.E., Rojo, F., She, Q.-B., Solit, D., Mills, G.B., Smith, D. et al. (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500-1508.
99. Oxley, J.D., Winkler, M.H., Gillatt, D.A. and Peat, D.S. ( 2002) Her-2/neu oncogene amplification in clinically localised prostate cancer. J Clin Pathol 55: 118-120.
100. Periman, P.O., Sonpavde, G. and Bernold, D.M. ( 2008) Sunitinib maleate for metastatic castration resistant prostate cancer following docetaxel-based chemotherapy. J Clin Oncol 26: abstract 5157.
101. Petrylak, D.P., Tangen, C.M., Hussain, M.H., Lara Jr, P.N., Jones, J.A., Taplin, M.E. et al. (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520.
102. Picus, J., Halabi, S., Rini, B., Vogelzang, N., Whang, Y., Kaplan, E. et al. (2003) The use of bevacizumab (B) with docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HRPC): initial results of CALGB 90006. Proc Am Soc Clin Oncol 22: (abstr 1578).
103. Reid, A.H., Attard, G., Danila, D., Ryan, C.J., Thompson, E., Kheoh, T. et al. (2009) A multicenter phase II study of abiraterone acetate (AA) in docetaxel pretreated castration-resistant prostate cancer (CRPC) patients (pts). J Clin Oncol 27(15s): abstr 5047.
104. Rokhlin, O.W., Glover, R.B., Guseva, N.V., Taghiyev, A.F., Kohlgraf, K.G. and Cohen, M.B. ( 2006) Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells. Mol Cancer Res 4: 113-123.
105. Rosenberg, J.E., Weinberg, V.K., Kelly, W.K., Michaelson, D., Hussain, M.H., Wilding, G. et al. (2007) Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 110: 556-563.
106. Rosenberg, J.E., Ryan, C.J., Weinberg, V.K., Smith, D.C., Hussain, M., Beer, T.M. et al. (2009) Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium. J Clin Oncol 27: 2772-2778.
107. Ross, R.W., Oh, W.K., Xie, W., Pomerantz, M., Nakabayashi, M., Sartor, O. et al. (2008 a) Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 26: 842-847.
108. Ross, R.W., Manola, J., Oh, W.K., Ryan, C., Kim, J., Rastarhuyeva, I. et al. (2008 b) Phase I trial of RAD 001 (R) and docetaxel (D) in castration resistant prostate cancer (CRPC) with FDG-PET assessment of RAD 001 activity. J Clin Oncol (Meeting Abstracts) 26: 5069.
109. Rowinsky, E.K., Youssoufian, H., Tonra, J.R., Solomon, P., Burtrum, D. and Ludwig, D.L. ( 2007) IMC-A12, a human IgG 1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 13: 5549-5555.
110. Ryan, C.J., Harzstark, A.H., Rosenberg, J., Lin, A., Claros, C., Goldfine, I.D. et al. (2008) A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer. BJU Int 101: 436-439.
111. Ryan, C., Efstathiou, E., Smith, M., Taplin, M., Bubley, G., Logothetis, C. et al. (2009) Phase II multicenter study of chemotherapy (chemo)-naive castration-resistant prostate cancer (CRPC) not exposed to ketoconazole (keto), treated with abiraterone acetate (AA) plus prednisone. J Clin Oncol 27(15s): abstr 5046.
112. Saad, F. ( 2009) Src as a therapeutic target in men with prostate cancer and bone metastases. BJU Int 103: 434-440.
113. Saad, F., Hotte, S.J. and North, S.A. ( 2008) A phase II randomized study of custirsen (OGX-011) combination therapy in patients with poor-risk hormone refractory cancer (HRPC) who relapsed on or within six months of 1st-line docetaxel therapy. J Clin Oncol 26(suppl): abstract 5002.
114. Scher, H.I. and Beer, T.M. ( 2009) Antitumor activity of MDV 3100 in a phase I / II study of castration-resistant prostate cancer (CRPC). J Clin Oncol 27: 15s; abstr 5011.
115. Scher, H.I., Halabi, S., Tannock, I., Morris, M., Sternberg, C.N., Carducci, M.A. et al. (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26: 1148-1159.
116. Sharifi, N., Dahut, W.L. and Figg, W.D. ( 2008) The genetics of castration-resistant prostate cancer: what can the germline tell us? Clin Cancer Res 14: 4691-4693.
117. Signoretti, S., Montironi, R., Manola, J., Altimari, A., Tam, C., Bubley, G. et al. (2000) Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 92: 1918-1925.
118. Simons, J.W. and Sacks, N. ( 2006) Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. Urol Oncol 24: 419-424.
119. Skowronski, R.J., Peehl, D.M. and Feldman, D. ( 1993) Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D 3 receptors and actions in human prostate cancer cell lines. Endocrinology 132: 1952-1960.
120. Slovin, S.F., Beer, T.M., Higano, C.S., Tejwani, S., Hamid, O., Picus, J. et al. (2009) Initial phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 27(15s): abstr 5138.
121. Smaletz, O., Kelly, W.K., Horse-Grant, D., Slovin, S.F., Morris, M.J., Solit, D.B. et al. (2002) Epothilone B analogue (BMS-247550) with estramustine phosphate in patients with progressive castrate-metastatic prostate cancer. Proceedings of the American Society of Clinical Oncology 21: 732.
122. Small, E.J., Reese, D.M., Um, B., Whisenant, S., Dixon, S.C. and Figg, W.D. ( 1999) Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res 5: 1738-1744.
123. Small, E.J., Fratesi, P., Reese, D.M., Strang, G., Laus, R., Peshwa, M.V. et al. (2000) Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 18: 3894-3903.
124. Small, E.J., Schellhammer, P.F., Higano, C.S., Redfern, C.H., Nemunaitis, J.J., Valone, F.H. et al. (2006) Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24: 3089-3094.
125. Small, E.J., Sacks, N., Nemunaitis, J., Urba, W.J., Dula, E., Centeno, A.S. et al. (2007 a) Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 13: 3883-3891.
126. Small, E.J., Tchekmedyian, N.S., Rini, B.I., Fong, L., Lowy, I. and Allison, J.P. ( 2007b) A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 13: 1810-1815.
127. Small, E., Harzstark, A., Weinberg, V.K., Smith, D.C., Mathew, P., Beer, T. et al. (2009 a) Ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer refractory to docetaxel-based therapy: a phase II study of the DOD Prostate Cancer Clinical Trials Consortium. J Clin Oncol 27(15s): abstr 5058.
128. Small, E., Demkow, T., Gerritsen, W.R., Rolland, F., Hoskin, P., Smith, D.C. et al. (2009 b) A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). ASCO Genitourinary Cancers Symposium (abstr 7).
129. Smith, M.R., Egerdie, B., Toriz, N.H., Feldman, R., Tammela, T.L., Saad, F. et al. (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361: 745-755.
130. Sternberg, C.N., Whelan, P., Hetherington, J., Paluchowska, B., Slee, P.H., Vekemans, K. et al. (2005) Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 68: 2-9.
131. Sternberg, C.N., Petrylak, D.P., Sartor, O., Witjes, J.A., Demkow, T., Ferrero, J.M. et al. (2009 a) Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 27: 5431-5438.
132. Sternberg, C.N., Dumez, H., van Poppel, H., Skoneczna, I., Sella, A., Daugaard, G. et al. (2009 b) Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Ann Oncol 20: 1264-1269.
133. Tannock, I.F., de Wit, R., Berry, W.R., Horti, J., Pluzanska, A., Chi, K.N. et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512.
134. Teo, S.K. ( 2005) Properties of thalidomide and its analogues: implications for anticancer therapy. AAPS J 7: E14-E19.
135. Titus, M.A., Schell, M.J., Lih, F.B., Tomer, K.B. and Mohler, J.L. ( 2005) Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 11: 4653-4657.
136. Tran, C., Ouk, S., Clegg, N.J., Chen, Y., Watson, P.A., Arora, V. et al. (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324: 787-90.
137. Tu, S.M., Mathew, P., Wong, F.C., Jones, D., Johnson, M.M. and Logothetis, C.J. ( 2009) Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer. J Clin Oncol 27: 3319-3324.
138. Verheul, H.M., Hammers, H., van Erp, K., Wei, Y., Sanni, T., Salumbides, B. et al. (2007) Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clin Cancer Res 13: 4201-4208.
139. Vijayakumar, S., Mehta, R.R., Boerner, P.S., Packianathan, S. and Mehta, R.G. ( 2005) Clinical trials involving vitamin D analogs in prostate cancer. Cancer J 11: 362-373.
140. Wang, X., Yu, J., Sreekumar, A., Varambally, S., Shen, R., Giacherio, D. et al. (2005) Autoantibody signatures in prostate cancer. N Engl J Med 353: 1224-1235.
141. Warren, T.L. and Weiner, G.J. ( 2000) Uses of granulocyte-macrophage colony-stimulating factor in vaccine development. Curr Opin Hematol 7: 168-173.
142. Weinstein, I.B. ( 2002) Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 297: 63-64.
143. Welsbie, D.S., Xu, J., Chen, Y., Borsu, L., Scher, H.I., Rosen, N. et al. (2009) Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res 69: 958-966.
144. Wu, X., Senechal, K., Neshat, M.S., Whang, Y.E. and Sawyers, C.L. ( 1998) The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A 95: 15587-15591.
145. Wu, J.D., Odman, A., Higgins, L.M., Haugk, K., Vessella, R., Ludwig, D.L. et al. (2005) In vivo effects of the human type I insulin-like growth factor receptor antibody A 12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res 11: 3065-3074.
146. Wu, S., Posadas, E. and Scripture, C. ( 2006) BAY 43-9006 (sorafenib) can lead to improvement of bone lesions in metastatic androgen-independent prostate cancer despite rises in serum PSA levels. Proceedings of the Prostate Cancer Symposium, Abstract 259. 24-26 February 2006. American Society of Clinical Oncology: Orlando, FL.
147. Yano, S., Herbst, R.S., Shinohara, H., Knighton, B., Bucana, C.D., Killion, J.J. et al. (2000) Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin Cancer Res 6: 957-965.
148. Zellweger, T., Chi, K., Miyake, H., Adomat, H., Kiyama, S., Skov, K. et al. (2002) Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin Cancer Res 8: 3276-3284.
149. Zhang, H., Kim, J.K., Edwards, C.A., Xu, Z., Taichman, R. and Wang, C.Y. ( 2005) Clusterin inhibits apoptosis by interacting with activated Bax. Nat Cell Biol 7: 909-915.
150. Ziada, A., Barqawi, A., Glode, L.M., Varella-Garcia, M., Crighton, F., Majeski, S. et al. (2004) The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate 60: 332-337.